Filing Flows › Spruce Biosciences (SPRB) › Recalls, complaints & regulation
Spruce Biosciences (SPRB): clinical trials
Spruce Biosciences (SPRB) beyond its filings: 1 active clinical trial.
Spruce Biosciences' latest quarter
Spruce Biosciences, Q4 2024: revenue $697K (-76% year over year), net loss $23.6M, operating cash flow −$20.7M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Spruce Biosciences have?
1 active study on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.